GE shares jump again as Wall Street loves the Danaher affair

Peter Lennox-King, an analyst at UBS, believes that this new source of liquidity for GE, as well as its benefits, is a boon for the company.

"The sale of GE BioPharma to Danaher actually raises the issue of leverage," Lennox-King said.

Deutsche Bank analyst Nicole DeBlase, however, was the intruder among the group, despite raising the group's target price on GE to $ 11 per share.

"GE is left with the less attractive parts of the healthcare industry," DeBlase said of the deal.

Here's what the leading Wall Street analysts said about the GE deal.